???global.info.a_carregar???
José Luís de Almeida (Luis Almeida, L Almeida). Concluiu o Doutoramento em Medicina em 1985 pela Universidade do Porto Faculdade de Medicina e Doutoramento em Medicina em 2008 pela Universidade do Porto Faculdade de Medicina. É fundador e Managing Director da BlueClinical - Investigação e Desenvolvimento em Saúde, Lda, uma empresa de investigação clínica. Publicou mais de 80 artigos em revistas especializadas.
Identificação

Identificação pessoal

Nome completo
José Luís de Almeida

Nomes de citação

  • Almeida, L
  • Luis Almeida

Identificadores de autor

Ciência ID
BD1A-8B53-9A4D
ORCID iD
0000-0002-4861-8649
Google Scholar ID
https://scholar.google.com/citations?user=0IDbXWIAAAAJ&hl=pt-PT

Domínios de atuação

  • Ciências Médicas e da Saúde - Ciências da Saúde
Formação
Grau Classificação
2008
Concluído
 Medicina (Doutoramento)
Especialização em Farmacologia Clínica
Universidade do Porto Faculdade de Medicina, Portugal
"Caracterização Psico-social de Voluntários Saudáveis em Ensaios Clínicos de Farmacologia Humana e Sua Correlação com os Resultados de Tolerabilidade e Farmacocinética" (TESE/DISSERTAÇÃO)
1979 - 1985
Concluído
 Medicina (Licenciatura)
Universidade do Porto Faculdade de Medicina, Portugal
 15
Percurso profissional

Docência no Ensino Superior

Categoria Profissional
Instituição de acolhimento 		Empregador
2009/04 - 2015 Professor Associado (Docente Universitário) Universidade de Aveiro, Portugal

Outras Carreiras

Categoria Profissional
Instituição de acolhimento 		Empregador
2012/05/08 - Atual Carreiras / Categorias Subsistentes BlueClinical - Investigação e Desenvolvimento em Saúde, Lda, Portugal
1996/06/01 - 2009/04/30 Carreiras / Categorias Subsistentes Bial - Portela & Cª SA, Portugal
1988/01/01 - 1996/04/30 Carreiras / Categorias Subsistentes Zyma Farmacêutica Portuguesa Lda, Portugal
1986/01/01 - 1987/12/31 Interno (Médica) Centro Hospitalar Universitário de São João, Portugal
Produções

Publicações

Artigo em conferência
  1. "Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor". 2010.
    10.1185/03007991003694472
  2. "Results of a double-blind, randomized, dose-titration, placebo controlled multicenter trial (SCO/BIA-2093-203 study) on safety and efficacy of eslicarbazepine acetate (BIA 2-093) for acute manic episodes associated with biopolar I disorder". 2010.
  3. "An Investigation of Effects of Eslicarbazepine Acetate on Hyponatremia: A Pooled Analysis of Three Double-Blind Phase III Clinical Studies". 2010.
  4. "An Evaluation of the Effect of Eslicarbazepine Acetate on Metabolic Parameters: A Pooled Analysis of Three Double-Blind Phase III Clinical Studies". 2010.
  5. "A double-blind, randomised, placebo-controlled rising dose study to investigate the tolerability and pharmacokinetics of etamicastat following repeated administration to healthy volunteers". 2009.
  6. "Interpersonal values of healthy subjects who volunteer for phase I clinical trials". 2009.
    10.2165/11531710-000000000-00000
  7. "Curiosity-trait of subjects who volunteer to phase I studies versus a control group.". 2007.
Artigo em revista
  1. Henriques SC; Paixão P; Almeida L; Silva NE. "Predictive Potential of Cmax Bioequivalence in Pilot Bioavailability/Bioequivalence Studies, through the Alternative ƒ2 Similarity Factor Method.". Pharmaceutics (2023): http://europepmc.org/abstract/med/37896259.
    10.3390/pharmaceutics15102498
  2. Gouveia R; Cruz VT; Antão J; Almeida L. "Interpersonal Values of Patients Participating in Phase II-III Clinical Trials: Implications for Clinical Trial Representativeness.". Pharmaceutical medicine (2023): http://europepmc.org/abstract/med/37249821.
    10.1007/s40290-023-00479-7
  3. Henriques SC; Albuquerque J; Paixão P; Almeida L; Silva NE. "Alternative Analysis Approaches for the Assessment of Pilot Bioavailability/Bioequivalence Studies.". Pharmaceutics (2023): http://europepmc.org/abstract/med/37242672.
    10.3390/pharmaceutics15051430
  4. Gouveia R; Cruz VT; Almeida L. "Sociodemographic and psychological characteristics influencing patients' willingness to participate in clinical trials.". BMJ open quality (2022): http://europepmc.org/abstract/med/36316063.
    10.1136/bmjoq-2022-002044
  5. Luis Almeida. "Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin". Drug Delivery and Translational Research 12 3 (2022): 629-646. http://dx.doi.org/10.1007/s13346-021-00972-z.
    10.1007/s13346-021-00972-z
  6. Luis Almeida. "Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis". Pharmaceutical Research 38 12 (2021): 2047-2063. http://dx.doi.org/10.1007/s11095-021-03136-3.
    10.1007/s11095-021-03136-3
  7. Luis Almeida. "Evaluation of Procalcitonin Accuracy for the Distinction Between Gram-Negative and Gram-Positive Bacterial Sepsis in Burn Patients". Journal of Burn Care & Research 40 1 (2019): 112-119. http://dx.doi.org/10.1093/jbcr/iry058.
    10.1093/jbcr/iry058
  8. Luis Almeida. "Disability and its clinical correlates in pulmonary hypertension measured through the World Health Organization Disability Assessment Schedule 2.0: a prospective, observational study". Jornal Brasileiro de Pneumologia 45 4 (2019): http://dx.doi.org/10.1590/1806-3713/e20170355.
    10.1590/1806-3713/e20170355
  9. Luis Almeida. "Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study". BioMed Research International 2018 (2018): 1-10. http://dx.doi.org/10.1155/2018/3924517.
    10.1155/2018/3924517
  10. Luis Almeida. "Procalcitonin for the early diagnosis of sepsis in burn patients: A retrospective study". Burns 43 7 (2017): 1427-1434. http://dx.doi.org/10.1016/j.burns.2017.03.026.
    10.1016/j.burns.2017.03.026
  11. Coutinho L; Oliveira H; Pacheco AR; Almeida L; Pimentel F; Santos C; Ferreira de Oliveira JM. "Hesperetin-etoposide combinations induce cytotoxicity in U2OS cells: Implications on therapeutic developments for osteosarcoma.". (2017): http://europepmc.org/abstract/med/28063664.
    10.1016/j.dnarep.2016.12.006
  12. Rocha, José-Francisco; Sicard, Éric; Fauchoux, Nicolas; Falcão, Amílcar; Santos, Ana; Loureiro, Ana I.; Pinto, Roberto; et al. "Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics". British Journal of Clinical Pharmacology 83 3 (2016): 540-553. http://dx.doi.org/10.1111/bcp.13156.
    Publicado • 10.1111/bcp.13156
  13. Reis A; Twiss J; Vicente M; Gonçalves F; Carvalho L; Meireles J; Melo A; McKenna SP; Almeida L. "Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire.". (2016): http://europepmc.org/abstract/med/27460644.
    10.1186/s12955-016-0513-8
  14. Luis Almeida. "Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease". Clinical Pharmacology in Drug Development 5 3 (2016): 232-240. http://dx.doi.org/10.1002/cpdd.217.
    10.1002/cpdd.217
  15. Cabral L; Afreixo V; Almeida L; Paiva JA. "The Use of Procalcitonin (PCT) for Diagnosis of Sepsis in Burn Patients: A Meta-Analysis.". (2016): http://europepmc.org/abstract/med/28005932.
    10.1371/journal.pone.0168475
  16. Grunze H; Kotlik E; Costa R; Nunes T; Falcão A; Almeida L; Soares-da-Silva P. "Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I.". (2015): http://europepmc.org/abstract/med/25484179.
    10.1016/j.jad.2014.11.013
  17. Luis Almeida. "Sulforaphane Induces Oxidative Stress and Death by p53-Independent Mechanism: Implication of Impaired Glutathione Recycling". PLoS ONE 9 3 (2014): e92980-e92980. http://dx.doi.org/10.1371/journal.pone.0092980.
    10.1371/journal.pone.0092980
  18. Almeida L; Nunes T; Costa R; Rocha JF; Vaz-da-Silva M; Soares-da-Silva P. "Etamicastat, a novel dopamine ß-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.". (2013): http://europepmc.org/abstract/med/24296323.
    10.1016/j.clinthera.2013.10.012
  19. Loureiro AI; Rocha JF; Fernandes-Lopes C; Nunes T; Wright LC; Almeida L; Soares-da-Silva P. "Human Disposition, Metabolism and Excretion of Etamicastat, a Reversible Peripherally Selective Dopamine ß-Hydroxylase Inhibitor.". (2013): http://europepmc.org/abstract/med/24168152.
    10.1111/bcp.12274
  20. Falcão A; Vaz-da-Silva M; Gama H; Nunes T; Almeida L; Soares-da-Silva P. "Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women.". (2013): http://europepmc.org/abstract/med/23570863.
    10.1016/j.eplepsyres.2013.02.020
  21. Elger C; Bialer M; Falcão A; Vaz-da-Silva M; Nunes T; Almeida L; Soares-da-Silva P. "Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.". (2013): http://europepmc.org/abstract/med/23758485.
    10.1111/epi.12242
  22. Almeida L; Rocha JF; Falcão A; Palma PN; Loureiro AI; Pinto R; Bonifácio MJ; et al. "Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.". (2013): http://europepmc.org/abstract/med/23248072.
    10.1007/s40262-012-0024-7
  23. Gil-Nagel, A.; Elger, C.; Ben-Menachem, E.; Halász, P.; Lopes-Lima, J.; Gabbai, A.A.; Nunes, T.; et al. "Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Integrated analysis of pooled data from double-blind phase III clinical studies". Epilepsia 54 1 (2013): 98-107. http://www.scopus.com/inward/record.url?eid=2-s2.0-84872077912&partnerID=MN8TOARS.
    10.1111/j.1528-1167.2012.03605.x
  24. Rocha, J.F.; Almeida, L.; Falcão, A.; Palma, P.N.; Loureiro, A.I.; Pinto, R.; Bonifácio, M.J.; et al. "Opicapone: A short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects". British Journal of Clinical Pharmacology 76 5 (2013): 763-775. http://www.scopus.com/inward/record.url?eid=2-s2.0-84886928771&partnerID=MN8TOARS.
    10.1111/bcp.12081
  25. Hufnagel, A.; Ben-Menachem, E.; Gabbai, A. A.; Falcao, A.; Almeida, L.; Soares-da-Silva, P.; B. I. A. Investigators Study. "Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study". Epilepsy Research 103 2-3 (2013): 262-269. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000315372600016&KeyUID=WOS:000315372600016.
    10.1016/j.eplepsyres.2012.07.014
  26. Nunes, T.; Rocha, J. F.; Falcao, A.; Almeida, L.; Soares-da-Silva, P.. "Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers". Epilepsia 54 1 (2013): 108-116. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000313116500018&KeyUID=WOS:000313116500018.
    10.1111/j.1528-1167.2012.03595.x
  27. Nunes, T.; Rocha, J. F.; Pinto, R.; Machado, R.; Wright, L.; Falcao, A.; Almeida, L.; Soares-da-Silva, P.. "Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel COMT inhibitor, during the first administration to healthy male subjects". European Journal of Neurology 19 (2012): 302-302. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000309359701206&KeyUID=WOS:000309359701206.
  28. Falcão, A.; Fuseau, E.; Nunes, T.; Almeida, L.; Soares-da-Silva, P.. "Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses". CNS Drugs 26 1 (2012): 79-91.
    3 [pii]10.2165/11596290-000000000-00000
  29. Vaz-da-Silva, Manuel; Nunes, Teresa; Almeida, Luis; Gutierrez, Maria J.; Litwin, Jeffrey S.; Soares-da-Silva, Patricio. "Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study". Journal of Clinical Pharmacology 52 2 (2012): 222-233. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000299657600008&KeyUID=WOS:000299657600008.
    10.1177/0091270010391789
  30. Perucca E; Elger C; Halász P; Falcão A; Almeida L; Soares-da-Silva P. "Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.". (2011): http://europepmc.org/abstract/med/21680153.
    10.1016/j.eplepsyres.2011.05.013
  31. Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P. "Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.". (2011): http://europepmc.org/abstract/med/21704242.
    10.1016/j.clinthera.2011.05.048
  32. Vaz-Da-Silva, M.; Nunes, T.; Rocha, J.F.; Falcão, A.; Almeida, L.; Soares-Da-Silva, P.. "Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453)". Drugs in R and D 11 2 (2011): 127-136. http://www.scopus.com/inward/record.url?eid=2-s2.0-79959413819&partnerID=MN8TOARS.
    10.2165/11587080-000000000-00000
  33. Rocha, J. F.; Vaz-da-Silva, M.; Nunes, T.; Igreja, B.; Loureiro, A. I.; Bonifácio, M. J.; Wright, L. C.; et al. "Single-Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5-453), a New Dopamine {beta}-Hydroxylase Inhibitor, in Healthy Subjects". J Clin Pharmacol (2011):
    0091270010390805 [pii]10.1177/0091270010390805
  34. Halász P; Cramer JA; Hodoba D; Czlonkowska A; Guekht A; Maia J; Elger C; et al. "Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy.". (2010): http://europepmc.org/abstract/med/20662896.
    10.1111/j.1528-1167.2010.02660.x
  35. Milovan D; Almeida L; Romach MK; Nunes T; Rocha JF; Sokowloska M; Sellers EM; Soares-da-Silva P. "Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers.". (2010): http://europepmc.org/abstract/med/20708576.
    10.1016/j.yebeh.2010.04.022
  36. Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P. "Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.". (2010): http://europepmc.org/abstract/med/20299189.
    10.1016/j.eplepsyres.2010.01.014
  37. Almeida L; Nunes T; Sicard E; Rocha JF; Falcão A; Brunet JS; Lefebvre M; Soares-da-Silva P. "Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects.". (2010): http://europepmc.org/abstract/med/20047572.
    10.1111/j.1600-0404.2009.01233.x
  38. Nunes T; Rocha JF; Vaz-da-Silva M; Igreja B; Wright LC; Falcão A; Almeida L; Soares-da-Silva P. "Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-ß-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects.". (2010): http://europepmc.org/abstract/med/21171669.
    10.2165/11586310-000000000-00000
  39. Vaz-da-Silva, M.; Almeida, L.; Falcão, A.; Soares, E.; Maia, J.; Nunes, T.; Soares-da-Silva, P.. "Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study". Clin Ther 32 1 (2010): 179-92.
    S0149-2918(10)00015-9 [pii]10.1016/j.clinthera.2010.01.014
  40. Vaz-da-Silva, M.; Almeida, L.; Falcão, A.; Soares, E.; Maia, J.; Nunes, T.; Soares-da-Silva, P.. "Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.". Clinical therapeutics 32 1 (2010): 179-192. http://www.scopus.com/inward/record.url?eid=2-s2.0-77952294567&partnerID=MN8TOARS.
  41. Wright, L.C.; Maia, J.; Loureiro, A.I.; Almeida, L.; Soares-Da-Silva, P.. "Pharmacokinetics, disposition, and metabolism of [14C]-Nebicapone in humans". Drug Metabolism Letters 4 3 (2010): 149-162. http://www.scopus.com/inward/record.url?eid=2-s2.0-78049432320&partnerID=MN8TOARS.
    10.2174/187231210791698465
  42. Nunes, T.; Sicard, E.; Almeida, L.; Falcão, A.; Rocha, J.-F.; Brunet, J.-S.; Lefebvre, M.; Soares-Da-Silva, P.. "Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects". Current Medical Research and Opinion 26 6 (2010): 1355-1362. http://www.scopus.com/inward/record.url?eid=2-s2.0-77952477242&partnerID=MN8TOARS.
    10.1185/03007991003740861
  43. Ferreira, J. J.; Rascol, O.; Poewe, W.; Sampaio, C.; Rocha, J. F.; Nunes, T.; Almeida, L.; Soares-da-Silva, P.; B. I. A. Study Investigators. "A Double-Blind, Randomized, Placebo and Active-Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease". Cns Neuroscience & Therapeutics 16 6 (2010): 337-347.
    10.1111/j.1755-5949.2010.00145.x
  44. Vaz da Silva M; Costa R; Soares E; Maia J; Falcão A; Almeida L; Soares da Silva P. "Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects.". (2009): http://europepmc.org/abstract/med/19500154.
    10.1111/j.1472-8206.2009.00691.x
  45. Nunes, T.; Almeida, L.; Rocha, J.-F.; Falcão, A.; Fernandes-Lopes, C.; Loureiro, A.I.; Wright, L.; Vaz-Da-Silva, M.; Soares-Da-Silva, P.. "Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects". Journal of Clinical Pharmacology 49 12 (2009): 1477-1482. http://www.scopus.com/inward/record.url?eid=2-s2.0-71449113221&partnerID=MN8TOARS.
    10.1177/0091270009339191
  46. Elger, C.; Halász, P.; Maia, J.; Almeida, L.; Soares-Da-Silva, P.. "Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study". Epilepsia 50 3 (2009): 454-463. http://www.scopus.com/inward/record.url?eid=2-s2.0-61849168486&partnerID=MN8TOARS.
    10.1111/j.1528-1167.2008.01946.x
  47. Almeida, L.; Vaz-da-Silva, M.; Falcão, A.; Soares, E.; Costa, R.; Loureiro, A.I.; Fernandes-Lopes, C.; et al. "Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers". Molecular Nutrition and Food Research 53 SUPPL. 1 (2009): http://www.scopus.com/inward/record.url?eid=2-s2.0-67649999248&partnerID=MN8TOARS.
    10.1002/mnfr.200800177
  48. Rocha, J.-F.; Vaz-da-Silva, M.; Almeida, L.; Falcão, A.; Nunes, T.; Santos, A.-T.; Martins, F.; et al. "Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects". International Journal of Clinical Pharmacology and Therapeutics 47 4 (2009): 255-261. http://www.scopus.com/inward/record.url?eid=2-s2.0-65549151370&partnerID=MN8TOARS.
  49. Nunes, T.; Machado, R.; Rocha, J.F.; Fernandes-Lopes, C.; Costa, R.; Torrão, L.; Loureiro, A.I.; et al. "Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: A single-center, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects". Clinical Therapeutics 31 10 (2009): 2258-2271. http://www.scopus.com/inward/record.url?eid=2-s2.0-71549165763&partnerID=MN8TOARS.
    10.1016/j.clinthera.2009.10.019
  50. Gil-Nagel, A.; Lopes-Lima, J.; Almeida, L.; Maia, J.; Soares-Da-Silva, P.. "Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures". Acta Neurologica Scandinavica 120 5 (2009): 281-287. http://www.scopus.com/inward/record.url?eid=2-s2.0-70349972675&partnerID=MN8TOARS.
    10.1111/j.1600-0404.2009.01218.x
  51. Almeida, L.; Kashdan, T.B.; Nunes, T.; Coelho, R.; Albino-Teixeira, A.; Soares-Da-Silva, P.. "Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events". European Journal of Clinical Pharmacology 64 6 (2008): 575-582. http://www.scopus.com/inward/record.url?eid=2-s2.0-84879254898&partnerID=MN8TOARS.
    10.1007/s00228-008-0468-8
  52. Almeida, L.; Falcão, A.; Vaz-da-Silva, M.; Coelho, R.; Albino-Teixeira, A.; Soares-da-Silva, P.. "Personality characteristics of volunteers in phase 1 studies and likelihood of reporting adverse events". International Journal of Clinical Pharmacology and Therapeutics 46 7 (2008): 340-348. http://www.scopus.com/inward/record.url?eid=2-s2.0-47549084636&partnerID=MN8TOARS.
  53. Almeida, L.; Minciu, I.; Nunes, T.; Butoianu, N.; Falcão, A.; Magureanu, S.-A.; Soares-Da-Silva, P.. "Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy". Journal of Clinical Pharmacology 48 8 (2008): 966-977. http://www.scopus.com/inward/record.url?eid=2-s2.0-47549103127&partnerID=MN8TOARS.
    10.1177/0091270008319706
  54. Almeida, L.; Falcão, A.; Vaz-Da-Silva, M.; Nunes, T.; Santos, A.-T.; Rocha, J.-F.; Neta, C.; et al. "Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects". European Journal of Clinical Pharmacology 64 10 (2008): 961-966. http://www.scopus.com/inward/record.url?eid=2-s2.0-53249083947&partnerID=MN8TOARS.
    10.1007/s00228-008-0534-2
  55. Almeida, L.; Coelho, R.; Albino-Teixeira, A.; Soares-da-Silva, P.. "Adverse non-drug-related complaints by healthy volunteers in Phase I studies compared to the healthy general population". International Journal of Clinical Pharmacology and Therapeutics 46 11 (2008): 574-583. http://www.scopus.com/inward/record.url?eid=2-s2.0-56749155871&partnerID=MN8TOARS.
  56. Vaz-da-Silva, M.; Loureiro, A.I.; Falcao, A.; Nunes, T.; Rocha, J.-F.; Fernandes-Lopes, C.; Soares, E.; et al. "Effect of food on the pharmacokinetic profile of trans-resveratrol". International Journal of Clinical Pharmacology and Therapeutics 46 11 (2008): 564-570. http://www.scopus.com/inward/record.url?eid=2-s2.0-56749153720&partnerID=MN8TOARS.
  57. Vaz-Da-Silva, M.; Loureiro, A.I.; Nunes, T.; Lopes, C.; Rocha, J.; MacHado, R.; Costa, R.; et al. "Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-O-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg: Randomized, double-blind, placebo-controlled, crossover study in healthy subjects". Drugs in R and D 9 6 (2008): 435-446. http://www.scopus.com/inward/record.url?eid=2-s2.0-55749092627&partnerID=MN8TOARS.
    10.2165/0126839-200809060-00006
  58. Fontes-Ribeiro, C.; MacEdo, T.; Nunes, T.; Neta, C.; Vasconcelos, T.; Cerdeira, R.; Lima, R.; et al. "Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: Randomized, open-label, crossover, single-centre study in healthy volunteers". Drugs in R and D 9 6 (2008): 447-454. http://www.scopus.com/inward/record.url?eid=2-s2.0-55749106790&partnerID=MN8TOARS.
    10.2165/0126839-200809060-00007
  59. Ferreira, J.J.; Almeida, L.; Cunha, L.; Ticmeanu, M.; Rosa, M.M.; Januário, C.; Mitu, C.-E.; et al. "Effects of nebicapone on levodopa pharmacokinetics, catechol-O- methyltransferase activity, and motor fluctuations in patients with Parkinson disease". Clinical Neuropharmacology 31 1 (2008): 2-18. http://www.scopus.com/inward/record.url?eid=2-s2.0-40049104890&partnerID=MN8TOARS.
    10.1097/wnf.0b013e3180645cb0
  60. Almeida, L.; Kashdan, T.B.; Coelho, R.; Albino-Teixeira, A.; Soares-da-Silva, P.. "Healthy subjects volunteering for phase I studies: Influence of curiosity, exploratory tendencies and perceived self-efficacy". International Journal of Clinical Pharmacology and Therapeutics 46 3 (2008): 109-118. http://www.scopus.com/inward/record.url?eid=2-s2.0-44249101190&partnerID=MN8TOARS.
  61. Almeida, L.; Potgieter, J.H.; Maia, J.; Potgieter, M.A.; Mota, F.; Soares-Da-Silva, P.. "Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment". European Journal of Clinical Pharmacology 64 3 (2008): 267-273. http://www.scopus.com/inward/record.url?eid=2-s2.0-43049177758&partnerID=MN8TOARS.
    10.1007/s00228-007-0414-1
  62. Maia, J.; Almeida, L.; Falcão, A.; Soares, E.; Mota, F.; Potgieter, M.A.; Potgieter, J.H.; Soares-da-Silva, P.. "Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate". International Journal of Clinical Pharmacology and Therapeutics 46 3 (2008): 119-130. http://www.scopus.com/inward/record.url?eid=2-s2.0-44249105976&partnerID=MN8TOARS.
  63. Almeida, L.; Falcão, A.; Coelho, R.; Albino-Teixeira, A.; Soares-Da-Silva, P.. "The role of socioeconomic conditions and psychological factors in the willingness to volunteer for phase I studies". Pharmaceutical Medicine 22 6 (2008): 367-374. http://www.scopus.com/inward/record.url?eid=2-s2.0-69549116806&partnerID=MN8TOARS.
    10.2165/1317117-200822060-00007
  64. Almeida L; Soares-da-Silva P. "Eslicarbazepine acetate (BIA 2-093).". (2007): http://europepmc.org/abstract/med/17199020.
    10.1016/j.nurt.2006.10.005
  65. Bonifácio MJ; Palma PN; Almeida L; Soares-da-Silva P. "Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.". (2007): http://europepmc.org/abstract/med/17894650.
    10.1111/j.1527-3458.2007.00020.x
  66. Elger, C.; Bialer, M.; Cramer, J.A.; Maia, J.; Almeida, L.; Soares-Da-Silva, P.. "Eslicarbazepine acetate: A double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures". Epilepsia 48 3 (2007): 497-504. http://www.scopus.com/inward/record.url?eid=2-s2.0-33847611166&partnerID=MN8TOARS.
    10.1111/j.1528-1167.2007.00984.x
  67. Falcão, A.; Maia, J.; Almeida, L.; Mazur, D.; Gellert, M.; Soares-da-Silva, P.. "Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker". Biopharmaceutics and Drug Disposition 28 5 (2007): 249-256. http://www.scopus.com/inward/record.url?eid=2-s2.0-34547553692&partnerID=MN8TOARS.
    10.1002/bdd.549
  68. Almeida, L.; Azevedo, B.; Nunes, T.; Vaz-Da-Silva, M.; Soares-Da-Silva, P.. "Why healthy subjects volunteer for phase I studies and how they perceive their participation?". European Journal of Clinical Pharmacology 63 11 (2007): 1085-1094. http://www.scopus.com/inward/record.url?eid=2-s2.0-35248865300&partnerID=MN8TOARS.
    10.1007/s00228-007-0368-3
  69. Loureiro, A.I.; Bonifácio, M.J.; Fernandes-Lopes, C.; Almeida, L.; Wright, L.C.; Soares-Da-Silva, P.. "Human metabolism of nebicapone (BIA 3-202), a novel catechol-O- methyltransferase inhibitor: Characterization of in vitro glucuronidation". Drug Metabolism and Disposition 34 11 (2006): 1856-1862. http://www.scopus.com/inward/record.url?eid=2-s2.0-33751107236&partnerID=MN8TOARS.
    10.1124/dmd.106.010447
  70. Maia J; Vaz-da-Silva M; Almeida L; Falcão A; Silveira P; Guimarães S; Graziela P; Soares-da-Silva P. "Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093).". (2005): http://europepmc.org/abstract/med/15991880.
    10.2165/00126839-200506040-00002
  71. Vaz-da-Silva M; Loureiro AI; Nunes T; Maia J; Tavares S; Falcão A; Silveira P; Almeida L; Soares-da-Silva P. "Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions.". (2005): http://europepmc.org/abstract/med/17532679.
    10.2165/00044011-200525060-00004
  72. Fontes-Ribeiro C; Nunes T; Falcão A; Neta C; Lima R; Tavares S; Almeida L; Macedo T; Soares-da-Silva P. "Eslicarbazepine acetate (BIA 2-093) : relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations.". (2005): http://europepmc.org/abstract/med/16128595.
    10.2165/00126839-200506050-00001
  73. Almeida, L.; Falcão, A.; Maia, J.; Mazur, D.; Gellert, M.; Soares-Da-Silva, P.. "Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects". Journal of Clinical Pharmacology 45 9 (2005): 1062-1066. http://www.scopus.com/inward/record.url?eid=2-s2.0-23944448566&partnerID=MN8TOARS.
    10.1177/0091270005279364
  74. Almeida L; Vaz-da-Silva M; Silveira P; Falcão A; Maia J; Loureiro A; Torrão L; et al. "Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa.". (2004): http://europepmc.org/abstract/med/15090932.
    10.1097/00002826-200401000-00007
  75. Almeida, L.; Soares-Da-Silva, P.. "Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans". Journal of Clinical Pharmacology 44 8 (2004): 906-918. http://www.scopus.com/inward/record.url?eid=2-s2.0-3242768230&partnerID=MN8TOARS.
    10.1177/0091270004267591
  76. Silveria, P.; Vaz-da-Silva, M.; Maia, J.; Almeida, L.; Gama, H.; Soares-da-Silva, P.. "Effects of enalapril and imidapril in the capsaicin cough challenge test and spirometry parameters in healthy volunteers". Therapy 1 2 (2004): 223-230. http://www.scopus.com/inward/record.url?eid=2-s2.0-23944524433&partnerID=MN8TOARS.
    10.1586/14750708.1.2.223
  77. Almeida L; Soares-da-Silva P. "Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans.". (2003): http://europepmc.org/abstract/med/12848585.
    10.2165/00126839-200304040-00001
  78. Almeida L; Soares-da-Silva P. "Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans.". (2003): http://europepmc.org/abstract/med/12952496.
    10.2165/00126839-200304050-00001
  79. SILVEIRA, P; VAZ-DA-SILVA, M; ALMEIDA, L; MAIA, J; FALCAO, A; LOUREIRO, A; TORRAO, L; et al. "Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide". European Journal of Clinical Pharmacology 59 8-9 (2003): 603-609.
    10.1007/s00228-003-0680-5
  80. ALMEIDA, L; SOARES-DA-SILVA, P. "Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects". Journal of Clinical Pharmacology 43 12 (2003): 1350-1360.
    10.1177/0091270003258666
  81. Fraga, A.; De Almeida, M.; Moreira-Da-Silva, V.; Sousa-Marques, M.; Severo, L.; Matos-Ferreira, A.; Campos-Pinheiro, L.; et al. "Intramuscular Etofenamate versus Diclofenac in the Relief of Renal Colic: A Randomised, Single-Blind, Comparative Study". Clinical Drug Investigation 23 11 (2003): 701-706. http://www.scopus.com/inward/record.url?eid=2-s2.0-10744232033&partnerID=MN8TOARS.
    10.2165/00044011-200323110-00002
  82. Silveira, P.; Vaz-Da-Silva, M.; Dolgner, A.; Almeida, L.. "Psychomotor effects of mexazolam vs placebo in healthy volunteers". Clinical Drug Investigation 22 10 (2002): 677-684. http://www.scopus.com/inward/record.url?eid=2-s2.0-0036394339&partnerID=MN8TOARS.
  83. Vaz-da-Silva, M.; Hainzl, D.; Almeida, L.; Dolgner, A.; Silveira, P.; Maia, J.; Soares-da-Silva, P.. "Relative bioavailability of two enteric-coated formulations of omeprazole following repeated doses in healthy volunteers". Clinical Drug Investigation 21 3 (2001): 203-210. http://www.scopus.com/inward/record.url?eid=2-s2.0-0035096528&partnerID=MN8TOARS.

Propriedade Intelectual

Patente
  1. 2010. "Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use". Estados Unidos.
  2. 2010. "Administration Regime for Nitrocathecols".
  3. 2006. "Eslicarbazepine acetate and methods of use".
  4. 2006. "Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use".
  5. 2006. "Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use". Estados Unidos.
  6. 2006. "Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use". Estados Unidos.